Close Menu
Home » Single-Cell Study Details Development of Chemoresistant Breast Cancer

Single-Cell Study Details Development of Chemoresistant Breast Cancer

Apr 19, 2018
|
staff reporter

NEW YORK (GenomeWeb) - A pilot study using single-cell sequencing to analyze the evolution of chemotherapy-resistant triple-negative breast cancer suggests that resistance arises from pre-existing clones with genetic mutations. However, transcriptional profiles associated with the cancer subtype can develop via reprogramming in response to chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
21
Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Oct
31
Featured Webinar

The Power of Automation for NGS Capture Enrichment: Uniformity and Speed

Sponsored by
PerkinElmer

This webinar will provide an overview of how the Center for Applied Genomics at Children's Hospital of Philadelphia has optimized its next-generation sequencing (NGS) workflow using a combination of PerkinElmer's Sciclone automation technology and target capture chemistry from Twist Bioscience.

What's Popular?

In Cancer

  1. Qiagen Nixes Sequencer Development, Sees New NGS Opportunities With Illumina Deal

    Premium

  2. Qiagen Partners With Illumina on NGS IVD Kits; CEO Departing; Preliminary Q3 Revenue Growth Lowered

  3. Mission Bio Lands $2M NCI SBIR Grant to Advance Minimal Residual Disease Detection

  4. Hopkins Team Develops Mass Spec Method to Detect Cancer Neoantigens

    Premium

  5. Bio-Techne Receives Medicare Coverage for Prostate Cancer Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.